Cambridge Investment Research Advisors Inc. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 5.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,835 shares of the medical research company’s stock after buying an additional 1,077 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in IQVIA were worth $4,908,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of IQV. Hanson & Doremus Investment Management lifted its stake in IQVIA by 300.0% in the 1st quarter. Hanson & Doremus Investment Management now owns 144 shares of the medical research company’s stock worth $29,000 after purchasing an additional 108 shares in the last quarter. AllSquare Wealth Management LLC acquired a new position in IQVIA during the first quarter worth $36,000. Financial Gravity Asset Management Inc. purchased a new stake in IQVIA in the 1st quarter valued at $1,989,000. Live Oak Investment Partners acquired a new stake in shares of IQVIA in the 4th quarter worth $41,000. Finally, Headlands Technologies LLC raised its holdings in shares of IQVIA by 62.3% during the 1st quarter. Headlands Technologies LLC now owns 224 shares of the medical research company’s stock worth $45,000 after acquiring an additional 86 shares during the period. 86.82% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Citigroup lifted their target price on shares of IQVIA from $200.00 to $225.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. HSBC began coverage on IQVIA in a research note on Wednesday, September 6th. They set a “buy” rating and a $260.00 target price for the company. Morgan Stanley upped their price target on IQVIA from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Wednesday, August 2nd. Truist Financial boosted their price objective on shares of IQVIA from $244.00 to $260.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. Finally, Stifel Nicolaus increased their target price on shares of IQVIA from $255.00 to $281.00 and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $252.00.
Insider Buying and Selling at IQVIA
In related news, insider Constantinos Panagos sold 27,317 shares of the business’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $208.67, for a total transaction of $5,700,238.39. Following the completion of the transaction, the insider now owns 14,250 shares in the company, valued at $2,973,547.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.
IQVIA Stock Performance
Shares of IQV stock opened at $202.39 on Tuesday. IQVIA Holdings Inc. has a 52 week low of $165.75 and a 52 week high of $241.86. The firm has a 50 day moving average of $218.64 and a two-hundred day moving average of $207.67. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 2.16. The stock has a market capitalization of $37.06 billion, a PE ratio of 34.83, a P/E/G ratio of 1.78 and a beta of 1.37.
IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Tuesday, August 1st. The medical research company reported $2.22 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.13. IQVIA had a return on equity of 30.14% and a net margin of 7.47%. The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.70 billion. On average, research analysts predict that IQVIA Holdings Inc. will post 9.24 EPS for the current fiscal year.
IQVIA Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
- Five stocks we like better than IQVIA
- What is the S&P/TSX Index?
- 2 Must-Have Silicon Companies That Don’t Make Microchips
- Overbought Stocks Explained: Should You Trade Them?
- Small Caps That Have Priced In A Hard Landing For Big Upside
- Investing in Commodities: What Are They? How to Invest in Them
- This May Have Ended Alibaba’s Winter, But Is It Time To Buy?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
